drugset / Trial / NCT04047940
A Study of LY900020 in Healthy Chinese Participants
RandomizedCrossoverOpen-labelBasic science
Summary
This study will evaluate three new formulations of LY900020; a fixed dose, combination drug developed for people with type 2 diabetes mellitus. The study will be conducted in healthy participants to investigate the effect of different tablet formulations on the amount of LY900020 in the bloodstream. Side effects and tolerability will be documented. The study will last about 10 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Timeline
- Start
- 2019-11-29
- Primary completion
- 2020-02-18
- Completion
- 2020-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY900020 | Unknown | — | Oral |
| Comparator | Atorvastatin | Small molecule | — | Oral |
| Comparator | Metformin | Small molecule | — | Oral |
| Comparator | Valsartan | Small molecule | — | Oral |
Indications
No indication recorded.